Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Why execution matters
View:
Post by N0taP00p on Feb 11, 2023 9:04pm

Why execution matters

Another small Toronto company that I bought into a dozen years ago for their amazing robotic surgery technology, hundreds of patents,  rolodex of big name surgeons on the advisory board, no debt, etc,  finally threw in the towel last week. Will probably find buyers for patents and designs.  Never seemed to attract big VC funding (which meant continuous dilution). The design was always getting tweaked, there were continuous delays and frequent funding cycles, many of them total surprises. I did buy into the rah-rah but ended up losing my money. 

At least Theralase has a phase 1 approval and FTD.   Now, it's all about execution and good communication.  Can't use the pandemic as a reason any more. Don't pull surprise raises and delays. Keep the shareholders informed every step of the way in a transparent manner. And above all, my lesson learned is look to for info from posters who are smart but not the blind-faith type.  There are a handful of good ones on this board.  It's your money, people. Let's hope we get some good news soon. It is overdue.
Comment by Rumpl3StiltSkin on Feb 12, 2023 9:53am
Poop,  We shareholders have very little to worry about, The Data is being collected by the clinicians running the trial. We are on their timeline. I think TLT has the funds in place to get us to that data. Then It is up to the market to catch up... A JV this year, probable. A buyout? Very possible. IMO. :-)
Comment by N0taP00p on Feb 12, 2023 5:15pm
From your keyboard to God's ears, Rumpl3. 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250